This review looked at how different antibiotics perform against Stenotrophomonas maltophilia, a type of bacteria that is often resistant to many drugs. The study compared four specific treatments: levofloxacin, minocycline, tigecycline, and TMP-SMX. The goal was to see which medications were most effective at improving survival and clinical response in patients with these difficult infections.
The results showed that levofloxacin significantly improved survival rates compared to TMP-SMX. While tigecycline showed the highest clinical response, it did not show a specific survival benefit in the data. Based on ranking systems, levofloxacin was ranked first for reducing mortality, while tigecycline was ranked first for overall clinical efficacy.
Because these infections are hard to treat, these findings suggest that levofloxacin might be a priority for critically ill patients. However, the evidence is based on a meta-analysis of existing data. Patients and doctors should discuss these specific treatment options and their risks with a medical professional to determine the best plan for individual care.
